Gilead Sciences | DŁUG



Debt Zmiana Data
AbbVie USD 67.14B 3.94B 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
ALKERMES USD 0 366M 2024-12
Alnylam Pharmaceuticals USD 1.02B 967K 2024-12
Amgen USD 60.1B 299M 2024-12
Biogen USD 6.3B 1.9M 2024-12
BioMarin Pharmaceutical USD 596.24M 1.61M 2024-12
Bristol-Myers Squibb USD 49.71B 62M 2025-03
Eli Lilly USD 38.52B 4.87B 2025-03
Gilead Sciences USD 26.71B 3.46B 2024-12
GlaxoSmithKline GBP 18.43B 1.45B 2025-03
Glaxosmithkline GBP 16.99B 927M 2024-12
Incyte USD 37.12M 840K 2025-03
J&J USD 52.25B 15.62B 2025-03
Merck USD 37.11B 1.02B 2024-12
Moderna USD 745M 683M 2025-03
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Pfizer USD 64.35B 3.35B 2024-12
PTC Therapeutics USD 2.39B 389K 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2025-03
Sanofi 21.05B 3.14B 2025-03
Sarepta Therapeutics USD 1.14B 90.44M 2024-12
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Gilead Sciences DŁUG - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.